This article was originally published in The Rose Sheet
Executive SummaryFourth quarter and fiscal year 2004 sales and earnings are expected to meet or exceed Wall Street estimates, firm says Sept. 22. Results are bolstered by Alberto's strategy of "advertising at record levels behind solid Alberto VO5, St. Ives and TRESemme product propositions, and by focusing on fewer and bigger brands, geographies and customers," according to CEO Howard Bernick. Alberto VO5, St. Ives, and TRESemme are all "more profitable today than ever before, and are better positioned than ever to continue to thrive in 2005 and future years here in the U.S. and overseas," exec adds...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.